598 related articles for article (PubMed ID: 22147903)
1. Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
Greve AM; Boman K; Gohlke-Baerwolf C; Kesäniemi YA; Nienaber C; Ray S; Egstrup K; Rossebø AB; Devereux RB; Køber L; Willenheimer R; Wachtell K
Circulation; 2012 Jan; 125(2):346-53. PubMed ID: 22147903
[TBL] [Abstract][Full Text] [Related]
2. Differences in cardiovascular risk profile between electrocardiographic hypertrophy versus strain in asymptomatic patients with aortic stenosis (from SEAS data).
Greve AM; Gerdts E; Boman K; Gohlke-Baerwolf C; Rossebø AB; Hammer-Hansen S; Køber L; Willenheimer R; Wachtell K
Am J Cardiol; 2011 Aug; 108(4):541-7. PubMed ID: 21624542
[TBL] [Abstract][Full Text] [Related]
3. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
4. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
[TBL] [Abstract][Full Text] [Related]
5. Impact of QRS duration and morphology on the risk of sudden cardiac death in asymptomatic patients with aortic stenosis: the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study.
Greve AM; Gerdts E; Boman K; Gohlke-Baerwolf C; Rossebø AB; Devereux RB; Køber L; Ray S; Willenheimer R; Wachtell K
J Am Coll Cardiol; 2012 Mar; 59(13):1142-9. PubMed ID: 22440214
[TBL] [Abstract][Full Text] [Related]
6. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
[TBL] [Abstract][Full Text] [Related]
8. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
9. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
Palmieri V; Okin PM; de Simone G; Bella JN; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2007 May; 25(5):1079-85. PubMed ID: 17414673
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of the electrocardiogram in predicting cardiovascular mortality in asymptomatic adults with aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
Greve AM; Dalsgaard M; Bang CN; Egstrup K; Rossebø AB; Boman K; Cramariuc D; Nienaber CA; Ray S; Gohlke-Baerwolf C; Okin PM; Devereux RB; Køber L; Wachtell K
Am J Cardiol; 2014 Sep; 114(5):751-6. PubMed ID: 25048345
[TBL] [Abstract][Full Text] [Related]
11. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
[TBL] [Abstract][Full Text] [Related]
12. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction.
Jander N; Minners J; Holme I; Gerdts E; Boman K; Brudi P; Chambers JB; Egstrup K; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Rossebø A; Pedersen TR; Skjærpe T; Willenheimer R; Wachtell K; Neumann FJ; Gohlke-Bärwolf C
Circulation; 2011 Mar; 123(8):887-95. PubMed ID: 21321152
[TBL] [Abstract][Full Text] [Related]
14. Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Palmieri V; Okin PM; Bella JN; Wachtell K; Oikarinen L; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2006 Oct; 24(10):2079-84. PubMed ID: 16957569
[TBL] [Abstract][Full Text] [Related]
15. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events.
Rieck ÅE; Cramariuc D; Boman K; Gohlke-Bärwolf C; Staal EM; Lønnebakken MT; Rossebø AB; Gerdts E
Hypertension; 2012 Jul; 60(1):90-7. PubMed ID: 22647889
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Heart; 2007 Jan; 93(1):59-64. PubMed ID: 16952975
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
Greve AM; Gerdts E; Boman K; Gohlke-Baerwolf C; Rossebø AB; Nienaber CA; Ray S; Egstrup K; Pedersen TR; Køber L; Willenheimer R; Wachtell K
Int J Cardiol; 2013 Jun; 166(1):72-6. PubMed ID: 21996417
[TBL] [Abstract][Full Text] [Related]
18. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
19. Relation of Left Ventricular Mass to Prognosis in Initially Asymptomatic Mild to Moderate Aortic Valve Stenosis.
Gerdts E; Rossebø AB; Pedersen TR; Cioffi G; Lønnebakken MT; Cramariuc D; Rogge BP; Devereux RB
Circ Cardiovasc Imaging; 2015 Nov; 8(11):e003644; discussion e003644. PubMed ID: 26489804
[TBL] [Abstract][Full Text] [Related]
20. The relationship between electrocardiographic left ventricular hypertrophy criteria and echocardiographic mass in patients undergoing transcatheter aortic valve replacement.
Sjöberg S; Sundh F; Schlegel T; Maynard C; Rück A; Wagner G; Ugander M
J Electrocardiol; 2015; 48(4):630-6. PubMed ID: 25865909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
